PerkinElmer buying antibody maker for $5.25B

PerkinElmer is buying antibody and reagents maker BioLegend in a $5.25 billion deal, the companies said July 26. 

Advertisement

The transaction, expected to close by the end of 2021, is the largest in PerkinElmer’s history. 

Under the deal, BioLegend’s San Diego campus will become PerkinElmer’s global center of excellence for research reagent content development. 

BioLegend has estimated 2022 revenue of $380 million. 

Read the full news release here. 

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.